The rumor mill churned out bad news for ImClone Systems Inc. Thursday when a German publication reported that Merck KGaA would not share its much-needed colorectal cancer trial data with ImClone for Erbitux. Throw in the release of first-quarter earnings that showed a greater-than-expected loss per share, and ImClone began Thursday with an 18 percent stock drop. (BioWorld Today)

The rumor mill churned out bad news for ImClone Systems Inc. Thursday when a German publication reported that Merck KGaA would not share its much-needed colorectal cancer trial data with ImClone for Erbitux. Throw in the release of first-quarter earnings that showed a greater-than-expected loss per share, and ImClone began Thursday with an 18 percent stock drop. (BioWorld Today)